Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (BEIGF) Accounts Payables (2016 - 2025)

BeOne Medicines (BEIGF) has disclosed Accounts Payables for 11 consecutive years, with $479.0 million as the latest value for Q4 2025.

  • Quarterly Accounts Payables rose 18.28% to $479.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $479.0 million through Dec 2025, up 18.28% year-over-year, with the annual reading at $479.0 million for FY2025, 18.28% up from the prior year.
  • Accounts Payables for Q4 2025 was $479.0 million at BeOne Medicines, up from $383.7 million in the prior quarter.
  • The five-year high for Accounts Payables was $479.0 million in Q4 2025, with the low at $146.9 million in Q1 2021.
  • Average Accounts Payables over 5 years is $297.9 million, with a median of $301.2 million recorded in 2022.
  • The sharpest move saw Accounts Payables skyrocketed 61.25% in 2022, then decreased 10.04% in 2024.
  • Over 5 years, Accounts Payables stood at $262.4 million in 2021, then grew by 12.34% to $294.8 million in 2022, then grew by 6.9% to $315.1 million in 2023, then rose by 28.53% to $405.0 million in 2024, then grew by 18.28% to $479.0 million in 2025.
  • According to Business Quant data, Accounts Payables over the past three periods came in at $479.0 million, $383.7 million, and $360.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.